dementia research studied mostly white trial volunteers and left out Black, Hispanic, Native American, Asian, older, poorer, and low-income-country groups. Data sharing also stalled from fragmented health systems and strict transfer rules, while privacy terms for AI companion tools stayed unclear.
For adults with memory concerns, that gap matters. Results may not apply evenly across groups, and joining a study or app can mean broad data use. The findings below show who was counted, who was missed, and what to check first.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Who was studied in treatment trials?
- Which other groups were missed?
- Why do diverse volunteers fail screening?
- Why can't researchers pool data across countries?
- What should families ask before joining?
- Frequently Asked Questions
Who was studied in treatment trials?
University of Illinois Chicago researchers found almost half of U.S. Alzheimer's treatment trials did not report race or ethnicity.
Among trials that did report, over 90% of participants identified as white, according to the UIC trial analysis. A separate review of Phase III anti-amyloid trials reported 83.20% Caucasian, 9.62% Asian, and 0.02% Native Hawaiian/Pacific Islander enrollment. White participants were overrepresented and Black participants were severely under-enrolled, according to the Phase III enrollment review.
Which other groups were missed?
An expert-informed UK Dementia Trials Network framework found the same pattern beyond the U.S. Ethnic minorities, socioeconomically deprived communities, adults over 75, and low- and middle-income country populations remain consistently underrepresented.
That limits generalizability. Generalizability means whether study results apply to people outside the study. When trials skew young, white, and affluent, doctors learn less about higher-risk Black, Hispanic, Native American, and Asian groups.
Why do diverse volunteers fail screening?
USC researchers studied 6,437 people in the AHEAD 3-45 lecanemab screening study. They found tau and amyloid blood-biomarker levels differ by race and ethnicity.
Tau and amyloid are brain proteins linked to Alzheimer's. Those differences affected trial eligibility and helped explain higher screen-failure rates for African American, Hispanic, and Asian cognitively unimpaired adults. Alzheimer's Disease International counted 158 potential therapies in 192 active trials in 2026 needing about 55,000 participants, yet about 350,000 volunteers must be screened because 44% of mild and 88% of preclinical candidates fail eligibility.
Why can't researchers pool data across countries?
Alzheimer Europe reported that fragmented national health-data systems, complex ethics approvals, and inconsistent data-protection interpretation block cross-country sharing. Public support is high, with 88% favoring sharing to speed progress, according to the Alzheimer Europe participation report.
A Health Data Research UK-commissioned report found complex international transfer laws impede brain-health data pooling. The result is global dementia estimates skewed by under-representation and underdiagnosis in minorities and low-income regions.
What should families ask before joining?
Duke's 2026-2027 project found persons living with dementia and care partners lack clear explanations of how commercial AI companion tools collect, store, and use data. That creates privacy risks when memory aids listen daily, according to the Duke privacy project description. Ask these questions before enrolling in a trial, registry, or app:.
- Who accesses my data, and for how long?
- Is data sold, shared with advertisers, or used to train AI?
- Can I delete data and withdraw without losing care?
- Are results and risks explained for my age and racial group?
Frequently Asked Questions
Will a trial result apply to me if my group was underrepresented?
It may apply less directly. Ask the study team how eligibility, biomarker cutoffs, and side-effect data relate to your age, race, and health conditions.
Does data sharing put my identity at risk?
Sharing can speed research, but rules vary by country and project. Ask what is shared, with whom, under what consent, and how deletion works.
You Might Also Like
- Smoking and Alcohol in the 2026 WHO Dementia Guideline: How Adults Over 65 Can Build a Realistic Brain Health Plan
- Cognitive Training in the 2026 WHO Dementia Guideline: How Adults Over 65 Can Build a Realistic Brain Health Plan
- Tailored Multidomain Risk Reduction in the 2026 WHO Guideline: How Adults Over 65 Can Build a Realistic Brain Health Plan
